ID 405335944 · FY 2020–2024 · 5 years
1.2 კომპანიის ძირითად საქმიანობას წარმოადგენს: - საბითუმო ვაჭრობა ფარმაცევტული საქონლითთავისუფალ ინდუსტრიულ ზონაში 1.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Ratio | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 27.5% | 41.9% | 46.9% | 37.4% | 39.6% |
| EBITDA Margin | -1.0% | 29.9% | 42.4% | 33.1% | 36.8% |
| EBITDAR | 11 | 1,892 | 3,205 | 2,328 | 3,099 |
| EBITDAR Margin | 0.5% | 30.4% | 42.8% | 33.5% | 37.3% |
| EBIT Margin | -1.3% | 29.7% | 42.3% | 33.1% | 36.7% |
| Net Profit Margin | 8.2% | 29.5% | 40.2% | 30.6% | 36.9% |
| Operating Expense % of Sales | 28.5% | 12.0% | 4.5% | 4.3% | 2.7% |
| Returns | |||||
| Return on Assets (ROA) | 7.1% | 49.6% | 49.1% | 29.6% | 29.1% |
| Return on Equity (ROE) | 176.9% | 179.3% | 127.8% | 112.1% | 87.4% |
| ROIC [EBIT / Invested Capital] | -133.4% | 216.7% | 150.4% | 162.8% | 89.7% |
| Leverage & liquidity | |||||
| Debt-to-Assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Debt-to-EBITDA | N/A | 0.00x | 0.00x | 0.00x | 0.00x |
| Equity-to-Assets | 4.0% | 27.7% | 38.4% | 26.4% | 33.3% |
| Net Debt | -81 | -170 | -249 | -485 | -110 |
| Cash & Equivalents | 81 | 170 | 249 | 485 | 110 |
| Total Debt | N/A | N/A | N/A | N/A | N/A |
| Efficiency & working capital | |||||
| Inventory Turnover | 1.27x | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | 288.2 | N/A | N/A | N/A | N/A |
| Receivables Turnover | 2.55x | 3.00x | 1.93x | 2.01x | 1.80x |
| Days Sales Outstanding (DSO) | 143.0 | 121.9 | 189.5 | 181.6 | 202.7 |
| Payables Turnover | 0.65x | 1.35x | 1.05x | 0.82x | 0.71x |
| Days Payable Outstanding (DPO) | 557.6 | 270.4 | 346.0 | 445.4 | 512.1 |
| Cash Conversion Cycle | -126.3 days | -148.6 days | -156.6 days | -263.8 days | -309.5 days |
| Asset Turnover | 0.87x | 1.68x | 1.22x | 0.96x | 0.79x |
| Cash flow & dividends | |||||
| Operating Cash Flow | 9 | 114 | 109 | N/A | N/A |
| Free Cash Flow (OCF − Capex proxy) | 9 | 114 | 109 | N/A | N/A |
| Cash Conversion (OCF / EBITDA) | N/A | 6.2% | 3.4% | N/A | N/A |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in ₾ '000. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.